Edison update - Worldwide Healthcare Trust

RNS Number : 0275U
Worldwide Healthcare Trust PLC
24 July 2015
 

 

London, UK, 24 July 2015

Edison issues research update on Worldwide Healthcare Trust

 

Worldwide Healthcare Trust (WWH) offers broad exposure to the global healthcare sector, including investments in healthcare services and medical devices alongside the more mainstream areas of pharmaceuticals and biotechnology. Healthcare has performed strongly in recent years, and WWH has outperformed its benchmark, the MSCI World Health Care Index, in three of the past four years to 30 June, particularly so in the last two years. While such strong performance may spark fears that a rerating is overdue, the manager points to continued favourable fundamentals for the sector, with the pace of drug discovery and an accommodative regulatory backdrop providing support.

 

At 20 July WWH's shares were trading at a 2.0% discount to cum-income NAV. This is narrower than the average discount over one, three and five years (4.6%, 4.6% and 6.1% respectively), but below the premium of 0.6% seen in late January, which was followed by a brief widening of the discount to 8% in early March. At the time of writing and after a sustained period of strong performance the shares were at a 52-week high, although NAV was 4% below its peak value.


Click here to view the full report

 

 

All reports published by Edison are available to download free of charge from its website.

www.edisoninvestmentresearch.com

 

 

About Edison: Edison, the investment intelligence firm, is the future of investor interaction with corporates. Our team of over 100 analysts and investment professionals works with leading companies, fund managers and investment banks worldwide to support their capital markets activity. We provide services to more than 400 retained corporate and investor clients from our offices in London, New York, Frankfurt, Sydney and Wellington. Edison is authorised and regulated by the Financial Conduct Authority (www.fsa.gov.uk/register/firmBasicDetails.do?sid=181584).

Edison is not an adviser or broker-dealer and does not provide investment advice. Edison's reports are not solicitations to buy or sell any securities.

Contact details: Learn more at www.edisongroup.com and connect with Edison on: 

LinkedIn

www.linkedin.com/company/edison-investment-research

Twitter

www.twitter.com/Edison_Inv_Res

YouTube

www.youtube.com/edisonitv

 

London
+44 (0)20 3077 5700

280 High Holborn

London,
WC1V 7EE

United Kingdom

New York
+1 646 653 7026

245 Park Avenue, 39th Floor

New York, NY 10167
US

Sydney
+61 (0)2 9258 1161

Level 25 Aurora Place
88 Philip Street

Sydney NSW 2000

Australia

Frankfurt
+49 (0)69 78 8076 960

Schumannstrasse
34b

60325 Frankfurt

Germany

 

 


This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
NRAPKQDPCBKKNOB
UK 100

Latest directors dealings